Revance's RT002 misses in Phase IIa for plantar fasciitis

Revance Therapeutics Inc. (NASDAQ:RVNC) said DaxibotulinumtoxinA for Injection (RT002) missed the primary endpoint of reducing patient-reported foot pain as measured by visual analog scale (VAS) score

Read the full 268 word article

User Sign In